Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Holding LEGN?
Track your performance easily
LEGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.17 - $70.13
Previous CloseN/A
Volume249.07K
Average Volume (3M)1.48M
Market Cap
$6.77B
Enterprise Value$8.07B
Total Cash (Recent Filing)$216.18M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 13, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding184,288,400
10 Day Avg. Volume1,836,000
30 Day Avg. Volume1,484,764
Standard Deviation0.14
R-Squared0.00284
Alpha0.00207
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)84.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue151.32
Enterprise Value/Gross Profit57.29
Enterprise Value/Ebitda-42.17
Forecast
1Y Price Target
$81.09Price Target Upside124.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Legend Biotech News
PremiumCompany Announcements
Legend Biotech Reports Q4 CARVYKTI® Sales
PremiumCompany Announcements
Legend Biotech Announces Employee Transition Agreement
Bulls Say, Bears Say
Bulls Say
Market PositionCarvykti has gained significant share (~36%) in 2-4L MM after two quarters of launch in early lines.
Safety ImprovementsEvolving data with new treatment protocols for Carvykti suggest that its previously observed delayed neurotoxicity rate could potentially be reduced, removing safety concerns.
Sales PerformanceCarvykti's sales beat expectations, showing strong growth and the best CART launch performance.
Bears Say
Competitive DynamicsConcerns remain of a world where Arcellx’s ddBCMA and CARVYKTI coexist commercially, with persistent investor questions about the market share splits.
Financial PerformanceThe company reported an earnings per share of $(0.34), slightly lower than the consensus estimate.
Safety ConcernsParkinsonism and secondary primary malignancies have been a frequent topic of discussion for CARVYKTI at the conference.
---
Ownership Overview
―
Insiders
17.25% Mutual Funds
0.03% Other Institutional Investors
80.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $30.17 and its highest was $70.13 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $6.77B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Mar 13, 2025 which is in 42 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Nov 12, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.01.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -0.25.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 184,288,400 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 0.35%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
---
Legend Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.09 (124.63% Upside)
$81.09 (124.63% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 7.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.9%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.58%
12-Months-Change
Fundamentals
Return on Equity
-31.19%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
---
LEGN Company Deck
---
LEGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, particularly the impressive revenue growth and survival benefit of CARVYKTI, along with expansion into new markets and manufacturing capabilities. However, these were tempered by increased net losses and foreign exchange challenges. The sentiment leans towards optimism due to strong product performance and strategic advancements.Read More>---
LEGN Stock 12 Month Forecast
Average Price Target
$81.09
▲(124.63% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Bluebird Bio
―
Crispr Therapeutics AG
―
Best Analysts Covering LEGN
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-5.53%
reiterated a buy rating last month
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -5.53% per trade.
---